NCT06238193

Brief Summary

The distribution rate of microsatellite instability-high (MSI-H) was significantly higher in early-onset colorectal cancer, and early-onset colorectal cancer has a specific mutational profile and relatively high programmed cell death ligand 1(PD-L1) expression, which may be used to guide personalized treatment to better control the disease.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11,344

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2003

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
20 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

January 22, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 2, 2024

Completed
Last Updated

February 2, 2024

Status Verified

February 1, 2024

Enrollment Period

20 years

First QC Date

January 22, 2024

Last Update Submit

February 1, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • MSI status

    (I) MSI-High (MSI-H) if two or more mononucleotide markers in tumor tissue had size variations of ≥3bp compared to normal tissue; (II) MSI-Low (MSI-L) if a single mononucleotide marker in tumor tissue exhibited a size variation of ≥3bp compared to normal tissue; (III) Microsatellite Stable (MSS) if there were no size variations of ≥3bp in mononucleotide markers in tumor tissue compared to normal tissue.

    Through study completion, an average of 1 year

Secondary Outcomes (1)

  • Copy-number variations (CNVs)

    Through study completion, an average of 1 year

Other Outcomes (1)

  • PD-L1 level

    Through study completion, an average of 1 year

Study Arms (2)

Early-onset colorectal cancer

Early-onset colorectal cancer

Late-onset colorectal cancer

Late-onset colorectal cancer

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

No.

You may qualify if:

  • Men and women aged 18-75 years old;
  • Histologically proven colon or rectal adenocarcinoma.

You may not qualify if:

  • Patients over 80 years of age;
  • Recurrent colorectal cancer;
  • Multiple primary tumors.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Colorectal NeoplasmsMicrosatellite Instability

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesGenomic InstabilityPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2024

First Posted

February 2, 2024

Study Start

January 1, 2003

Primary Completion

December 31, 2022

Study Completion

January 1, 2024

Last Updated

February 2, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share